HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT)
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $60.00 target price on the biotechnology company’s stock. A number of other equities analysts have also issued reports on the company. Cantor Fitzgerald […]
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $60.00 target price on the biotechnology company’s stock. A number of other equities analysts have also issued reports on the company. Cantor Fitzgerald […]